Cargando…

First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1

BACKGROUND: Live, attenuated viral vectors that express HIV-1 antigens are being investigated as an approach to generating durable immune responses against HIV-1 in humans. We recently developed a replication-competent, highly attenuated Ad26 vector that expresses mosaic HIV-1 Env (rcAd26.MOS1.HIV-E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stephenson, Kathryn E., Keefer, Michael C., Bunce, Catherine A., Frances, Doreen, Abbink, Peter, Maxfield, Lori F., Neubauer, George H., Nkolola, Joseph, Peter, Lauren, Lane, Christopher, Park, Harriet, Verlinde, Carl, Lombardo, Angela, Yallop, Christopher, Havenga, Menzo, Fast, Patricia, Treanor, John, Barouch, Dan H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235250/ https://www.ncbi.nlm.nih.gov/pubmed/30427829 http://dx.doi.org/10.1371/journal.pone.0205139

Ejemplares similares

Development of replication-competent adenovirus based vaccine vectors
por: Abbink, P, et al.
Publicado: (2012)

Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization
por: Maxfield, Lori F., et al.
Publicado: (2015)

Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys
por: Keele, Brandon F., et al.
Publicado: (2017)

Genetic heterogeneity in response to adenovirus gene therapy
por: Lefesvre, Pierre, et al.
Publicado: (2003)

Development of a novel simian adenovirus 24 based vaccine vector
por: Abbink, P, et al.
Publicado: (2012)

Adenovirus serotype 26 utilizes CD46 as primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys
por: Li, H, et al.
Publicado: (2012)

Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors
por: Abbink, Peter, et al.
Publicado: (2018)

Alpha-defensin 5 differentially modulates adenovirus vaccine vectors from different serotypes in vivo
por: Tartaglia, Lawrence J., et al.
Publicado: (2019)

Human species D adenovirus hexon capsid protein mediates cell entry through a direct interaction with CD46
por: Persson, B. David, et al.
Publicado: (2021)

A microbial expression system for high-level production of scFv HIV-neutralizing antibody fragments in Escherichia coli
por: Petrus, Marloes L. C., et al.
Publicado: (2019)

Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine
por: Hamidi, Ahd, et al.
Publicado: (2021)

P17-22. Impact of rare adenovirus seroprevalence on HIV-1 acquisition in the Step study
por: Maxfield, LF, et al.
Publicado: (2009)

Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys
por: Liu, Jinyan, et al.
Publicado: (2008)

Activation of coagulation and proinflammatory pathways in thrombosis with thrombocytopenia syndrome and following COVID-19 vaccination
por: Aid, Malika, et al.
Publicado: (2023)

Ex Vivo Expansion of Hematopoietic Stem Cells for Therapeutic Purposes: Lessons from Development and the Niche
por: Tajer, Parisa, et al.
Publicado: (2019)

OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector
por: Baden, LR, et al.
Publicado: (2009)

Broad HIV Epitope Specificity and Viral Inhibition Induced by Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults
por: Kopycinski, Jakub, et al.
Publicado: (2014)

Accelerated heterologous prime-boost adenovirus vector-based SIV vaccine in neonatal rhesus monkeys
por: Liu, J, et al.
Publicado: (2012)

Adenovirus vectors from various serotypes induce distinct cytokine profiles
por: Teigler, JE, et al.
Publicado: (2012)

A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults
por: Keefer, Michael C., et al.
Publicado: (2012)

Firewalls Prevent Systemic Dissemination of Vectors Derived from Human Adenovirus Type 5 and Suppress Production of Transgene-Encoded Antigen in a Murine Model of Oral Vaccination
por: Revaud, Julien, et al.
Publicado: (2018)

Stability and neutralization capacity of a novel mosaic HIV-1 gp140 trimer in a guinea pig model
por: Nkolola, JP, et al.
Publicado: (2012)

Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5–based Constructs
por: Alonso-Padilla, Julio, et al.
Publicado: (2016)

Vaccine Protection Against Zika Virus from Brazil
por: Larocca, Rafael A., et al.
Publicado: (2016)

A global approach to HIV-1 vaccine development
por: Stephenson, Kathryn E, et al.
Publicado: (2013)

Broadly Neutralizing Antibodies for HIV Eradication
por: Stephenson, Kathryn E., et al.
Publicado: (2016)

HIV-1 envelope trimer elicits higher neutralizing antibody responses than monomeric gp120
por: Kovacs, JM, et al.
Publicado: (2012)

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
por: López-Camacho, César, et al.
Publicado: (2019)

Future of adenoviruses in the gene therapy of arthritis
por: Evans, Christopher H, et al.
Publicado: (2001)

Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors
por: Iampietro, M. Justin, et al.
Publicado: (2018)

Different memory T cell phenotypes are elicited by Ad5 and rare adenoviruses
por: Penaloza, P, et al.
Publicado: (2012)

Explosion investigation
por: Yallop, H John
Publicado: (1980)

P10-06. Adaptive immune responses elicited by recombinant adenovirus vectors exhibit partial MyD88 dependence
por: Rhee, EG, et al.
Publicado: (2009)

HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys
por: Moldt, Brian, et al.
Publicado: (2022)

Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial
por: Stephenson, Kathryn E., et al.
Publicado: (2021)

Antibody and TLR7 Agonist Delay Viral Rebound in SHIV-Infected Monkeys
por: Borducchi, Erica N., et al.
Publicado: (2018)

Oncolytic Adenovirus in Cancer Immunotherapy
por: Peter, Malin, et al.
Publicado: (2020)

Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy
por: Watanabe, Maki, et al.
Publicado: (2021)

Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
por: Julg, Boris, et al.
Publicado: (2022)

IMMUNOFLUORESCENT STUDIES OF ADENOVIRUS 12 TUMORS AND OF CELLS TRANSFORMED OR INFECTED BY ADENOVIRUSES
por: Pope, John H., et al.
Publicado: (1964)

Cannot write session to /tmp/vufind_sessions/sess_m7vmqsoluperobaa1m437evl75